{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T07:11:56Z","timestamp":1778310716279,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00535-026-02366-9","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T14:10:33Z","timestamp":1771683033000},"page":"536-546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A phase I\/II clinical trial of neoadjuvant docetaxel\/oxaliplatin\/S\u20111 (DOS) combination therapy for gastroesophageal junction adenocarcinoma"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6165-5105","authenticated-orcid":false,"given":"Koshi","family":"Kumagai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Hosoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikatoshi","family":"Katada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Ishido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinori","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Niihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikiko","family":"Sakuraya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Washio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohiro","family":"Chuman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Okuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keishi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Kumamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Naitoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chika","family":"Kusano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"issue":"11","key":"2366_CR1","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1046\/j.1365-2168.1998.00940.x","volume":"85","author":"JR Siewert","year":"1998","unstructured":"Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85(11):1457\u20139. https:\/\/doi.org\/10.1046\/j.1365-2168.1998.00940.x.","journal-title":"Br J Surg"},{"issue":"8","key":"2366_CR2","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/sj.bjc.6600252","volume":"86","author":"J Wayman","year":"2002","unstructured":"Wayman J, Bennett MK, Raimes SA, Griffin SM. The pattern of recurrence of adenocarcinoma of the oesophago-gastric junction. Br J Cancer. 2002;86(8):1223\u20139. https:\/\/doi.org\/10.1038\/sj.bjc.6600252.","journal-title":"Br J Cancer"},{"issue":"10184","key":"2366_CR3","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(18)32557-1.","journal-title":"Lancet"},{"issue":"22","key":"2366_CR4","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BPL, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074\u201384. https:\/\/doi.org\/10.1056\/NEJMoa1112088.","journal-title":"N Engl J Med"},{"key":"2366_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1186\/s12885-016-2564-y","volume":"16","author":"J Hoeppner","year":"2016","unstructured":"Hoeppner J, Lordick F, Brunner T, Glatz T, Bronsert P, R\u00f6thling N, et al. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus. BMC Cancer. 2016;16:503. https:\/\/doi.org\/10.1186\/s12885-016-2564-y.","journal-title":"BMC Cancer"},{"issue":"17_suppl","key":"2366_CR6","doi-asserted-by":"publisher","first-page":"LBA4000","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4000","volume":"41","author":"J Hoeppner","year":"2023","unstructured":"Hoeppner J, Lordick F, Brunner T, et al. Perioperative FLOT versus preoperative chemoradiation (CROSS) in patients with resectable esophageal or gastroesophageal junction adenocarcinoma: the randomized controlled ESOPEC trial. J Clin Oncol. 2023;41(17_suppl):LBA4000. https:\/\/doi.org\/10.1200\/JCO.2023.41.17_suppl.LBA4000.","journal-title":"J Clin Oncol"},{"issue":"18","key":"2366_CR7","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810\u201320. https:\/\/doi.org\/10.1056\/NEJMoa072252.","journal-title":"N Engl J Med"},{"issue":"15","key":"2366_CR8","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1200\/JCO.18.01138","volume":"37","author":"K Yoshida","year":"2019","unstructured":"Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37(15):1296\u2013304. https:\/\/doi.org\/10.1200\/JCO.18.01138.","journal-title":"J Clin Oncol"},{"key":"2366_CR9","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00280-013-2257-z","volume":"72","author":"I Park","year":"2013","unstructured":"Park I, Ryu MH, Choi YH, Kang HJ, Yook JH, Park YS, et al. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma. Cancer Chemother Pharmacol. 2013;72:815\u201323. https:\/\/doi.org\/10.1007\/s00280-013-2257-z.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"26","key":"2366_CR10","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.20.02914","volume":"39","author":"YK Kang","year":"2021","unstructured":"Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, et al. PRODIGY: phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol. 2021;39(26):2903\u201313. https:\/\/doi.org\/10.1200\/JCO.20.02914.","journal-title":"J Clin Oncol"},{"issue":"25","key":"2366_CR11","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/JCO.23.02167","volume":"42","author":"YK Kang","year":"2024","unstructured":"Kang YK, Kim HD, Yook JH, Park YK, Lee JS, Kim YW, et al. Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 for resectable advanced gastric cancer: updated overall survival outcomes from phase III PRODIGY. J Clin Oncol. 2024;42(25):2961\u20135. https:\/\/doi.org\/10.1200\/JCO.23.02167.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2366_CR12","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s10120-023-01453-7","volume":"27","author":"Y Kurokawa","year":"2024","unstructured":"Kurokawa Y, Doki Y, Kitabayashi R, Yoshikawa T, Nomura T, Tsuji K, et al. Short-term outcomes of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis (JCOG1704). Gastric Cancer. 2024;27(2):366\u201374. https:\/\/doi.org\/10.1007\/s10120-023-01453-7.","journal-title":"Gastric Cancer"},{"issue":"5","key":"2366_CR13","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1007\/s10120-022-01300-1","volume":"25","author":"T Saito","year":"2022","unstructured":"Saito T, Kurokawa Y, Takahashi T, Yamamoto K, Yamashita K, Tanaka K, et al. Neoadjuvant docetaxel, oxaliplatin and S-1 (DOS) combination chemotherapy for patients with resectable adenocarcinoma of esophagogastric junction. Gastric Cancer. 2022;25(5):966\u201372. https:\/\/doi.org\/10.1007\/s10120-022-01300-1.","journal-title":"Gastric Cancer"},{"issue":"2","key":"2366_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10388-014-0422-z","volume":"11","author":"N Katada","year":"2014","unstructured":"Katada N, Yamashita K, Katada C, et al. Neoadjuvant chemotherapy using concurrent Docetaxel\/CDDP\/5-FU (DCF) in esophageal squamous cell carcinoma and its short-term prognosis. Esophagus. 2014;11(2):173\u201381. https:\/\/doi.org\/10.1007\/s10388-014-0422-z.","journal-title":"Esophagus"},{"issue":"2","key":"2366_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s11748-016-0626-3","volume":"64","author":"K Yamashita","year":"2016","unstructured":"Yamashita K, Katada N, Moriya H, et al. Neoadjuvant chemotherapy of triplet regimens of docetaxel\/cisplatin\/5-FU (DCF NAC) may improve patient prognosis of cStage II\/III esophageal squamous cell carcinoma\u2014propensity score analysis. Gen Thorac Cardiovasc Surg. 2016;64(2):209\u201315. https:\/\/doi.org\/10.1007\/s11748-016-0626-3.","journal-title":"Gen Thorac Cardiovasc Surg"},{"issue":"6","key":"2366_CR16","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1007\/s10147-020-01638-5","volume":"25","author":"K Hosoda","year":"2020","unstructured":"Hosoda K, Azuma M, Katada C, Ishido K, Niihara M, Ushiku H, et al. A phase I study of docetaxel\/oxaliplatin\/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction. Int J Clin Oncol. 2020;25(6):1090\u20137. https:\/\/doi.org\/10.1007\/s10147-020-01638-5.","journal-title":"Int J Clin Oncol"},{"key":"2366_CR17","doi-asserted-by":"publisher","unstructured":"Sobin LH, Gospodarowicz MK, Wittekind C (Eds) TNM classification of malignant tumours. 7th ed. Oxford: Wiley-Blackwell; 2009. https:\/\/doi.org\/10.1002\/9780471420194.tnmc26.pub2.","DOI":"10.1002\/9780471420194.tnmc26.pub2"},{"issue":"6","key":"2366_CR18","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649\u201355. https:\/\/doi.org\/10.1097\/00000421-198212000-00014.","journal-title":"Am J Clin Oncol"},{"key":"2366_CR19","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. National Cancer Institute; 2009. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"},{"issue":"2","key":"2366_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"issue":"2","key":"2366_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae.","journal-title":"Ann Surg"},{"issue":"2","key":"2366_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10120-011-0041-5","volume":"14","author":"Japanese Gastric Cancer Association","year":"2011","unstructured":"Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101\u201312. https:\/\/doi.org\/10.1007\/s10120-011-0041-5.","journal-title":"Gastric Cancer"},{"issue":"3","key":"2366_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant"},{"key":"2366_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-025-01603-z","author":"N Hiki","year":"2025","unstructured":"Hiki N, Higuchi T, Kumagai K, Okuno K, Minoura H, Sato Y, et al. Appetite-preserving gastrectomy (APG) for esophagogastric junction cancer: preserving the residual stomach as an endocrine organ. Gastric Cancer. 2025. https:\/\/doi.org\/10.1007\/s10120-025-01603-z.","journal-title":"Gastric Cancer"},{"issue":"7","key":"2366_CR25","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/cncr.21346","volume":"104","author":"PR Rohatgi","year":"2005","unstructured":"Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, et al. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer. 2005;104(7):1349\u201355. https:\/\/doi.org\/10.1002\/cncr.21346.","journal-title":"Cancer"},{"issue":"2","key":"2366_CR26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10388-024-01043-1","volume":"21","author":"T Yano","year":"2024","unstructured":"Yano T, Hayashi Y, Ishihara R, Iijima K, Iwakiri K, Uesato M, et al. Remarkable response as a new indicator for endoscopic evaluation of local efficacy of non-surgical treatments for esophageal cancer. Esophagus. 2024;21(2):85\u201394. https:\/\/doi.org\/10.1007\/s10388-024-01043-1.","journal-title":"Esophagus"},{"issue":"5","key":"2366_CR27","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.ijrobp.2024.06.019","volume":"120","author":"C Katada","year":"2024","unstructured":"Katada C, Yokoyama T, Watanabe A, Hara H, Yoshii T, Fujii H, et al. Optimizing organ-preservation strategies through chemotherapy-based selection in esophageal squamous cell carcinoma: results from the CROC multi-institutional phase 2 clinical trial. Int J Radiat Oncol Biol Phys. 2024;120(5):1353\u201362. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.06.019.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2366_CR28","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/jjco\/hyad149","volume":"54","author":"R Kita","year":"2024","unstructured":"Kita R, Yanagimoto Y, Imazeki H, Booka E, Tsushima T, Mizusawa J, et al. Protocol digest of a randomized controlled adaptive phase II\/III trial of neoadjuvant chemotherapy for Japanese patients with oesophagogastric junction adenocarcinoma: Japan Clinical Oncology Group Study JCOG2203 (NEO-JPEG). Jpn J Clin Oncol. 2024;54(2):206\u201311. https:\/\/doi.org\/10.1093\/jjco\/hyad149.","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"2366_CR29","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz LS, Enzinger PC, Yoon HH, Moehler M, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25(2):212\u201324. https:\/\/doi.org\/10.1016\/S1470-2045(23)00541-7.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2366_CR30","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","volume":"393","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med. 2025;393(3):217\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2503701.","journal-title":"N Engl J Med"},{"issue":"28","key":"2366_CR31","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33(28):3199\u2013212. https:\/\/doi.org\/10.1200\/JCO.2015.62.3488.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2366_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8\u201332. https:\/\/doi.org\/10.1016\/j.ejca.2010.10.013.","journal-title":"Eur J Cancer"},{"issue":"2","key":"2366_CR33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/jjco\/hyaa224","volume":"51","author":"C Katada","year":"2021","unstructured":"Katada C, Sugawara M, Hara H, Fujii H, Eguchi Nakajima T, Ando T, et al. A management of neutropenia using granulocyte colony-stimulating factor support for chemotherapy consisting of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma. Jpn J Clin Oncol. 2021;51(2):199\u2013204. https:\/\/doi.org\/10.1093\/jjco\/hyaa224.","journal-title":"Jpn J Clin Oncol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02366-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-026-02366-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02366-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T06:41:25Z","timestamp":1778308885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-026-02366-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2366"],"URL":"https:\/\/doi.org\/10.1007\/s00535-026-02366-9","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Several authors have received honoraria, lecture fees, or research funding from pharmaceutical or device companies, as detailed in their disclosure forms. All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}